

Clinical Note

Patient Name: John Smith

Date of Birth: 1965-03-15

Date of Note: November 18, 2025

Diagnosis & Disease Status

Primary Diagnosis: Lung cancer

ICD-10 Code: C34.90

Disease Stage: Stage IIIB (Note: Assumed based on platinum chemotherapy prior)

Performance Status: ECOG 1 (Note: Assumed for active treatment)

Clinical History

Prior Therapies:

- Platinum chemotherapy

Current Line of Therapy:

- Second-line (post-platinum chemotherapy)

Medication History:

- Platinum chemotherapy

Biomarker & Laboratory Results

Biomarker / Test	Result	Comments
PD-L1	65%	Predicts pembrolizumab response
EGFR / ALK	Negative	No targetable mutation

Assessment & Plan

Assessment:

Patient with Stage IIIB lung cancer, status post-platinum chemotherapy. Biomarker analysis reveals PD-L1 expression of 65% and negative EGFR/ALK status, supporting the use of immunotherapy.

Treatment Plan:

- Planned Treatment:** Pembrolizumab

Insurance Information

Provider: UnitedHealth

Policy ID: INS12345

Coverage Period: 2025-01-01 to 2025-12-31

Eligibility Status: ACTIVE